CRDF Valuation

Cardiff Oncology Inc

Add to Watchlist

Advanced Chart

2.100

+0.02(0.962%)1D

Overview
Forecast
Valuation
Earnings

CRDF Relative Valuation

CRDF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRDF is overvalued; if below, it's undervalued.

Historical Valuation

Cardiff Oncology Inc (CRDF) is now in the Fair zone, suggesting that its current forward PS ratio of 346.75 is considered Fairly compared with the five-year average of -5.74. The fair price of Cardiff Oncology Inc (CRDF) is between 0.41 to 7.59 according to relative valuation methord.

Relative Value

Fair Zone

0.41-7.59

Current Price：2.10

Fair

-2.50

Trailing

Forward

0.00

EV/EBITDA

Cardiff Oncology Inc. (CRDF) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-1.15

EV/EBIT

Cardiff Oncology Inc. (CRDF) has a current EV/EBIT of -1.15. The 5-year average EV/EBIT is -3.16. The thresholds are as follows: Strongly Undervalued below -15.56, Undervalued between -15.56 and -9.36, Fairly Valued between 3.03 and -9.36, Overvalued between 3.03 and 9.23, and Strongly Overvalued above 9.23. The current Forward EV/EBIT of -1.15 falls within the Historic Trend Line -Fairly Valued range.

346.75

Cardiff Oncology Inc. (CRDF) has a current PS of 346.75. The 5-year average PS is 804.86. The thresholds are as follows: Strongly Undervalued below -678.59, Undervalued between -678.59 and 63.13, Fairly Valued between 1546.58 and 63.13, Overvalued between 1546.58 and 2288.31, and Strongly Overvalued above 2288.31. The current Forward PS of 346.75 falls within the Historic Trend Line -Fairly Valued range.

-2.61

P/OCF

Cardiff Oncology Inc. (CRDF) has a current P/OCF of -2.61. The 5-year average P/OCF is -4.44. The thresholds are as follows: Strongly Undervalued below -20.17, Undervalued between -20.17 and -12.30, Fairly Valued between 3.42 and -12.30, Overvalued between 3.42 and 11.29, and Strongly Overvalued above 11.29. The current Forward P/OCF of -2.61 falls within the Historic Trend Line -Fairly Valued range.

-2.62

P/FCF

Cardiff Oncology Inc. (CRDF) has a current P/FCF of -2.62. The 5-year average P/FCF is -5.42. The thresholds are as follows: Strongly Undervalued below -18.27, Undervalued between -18.27 and -11.85, Fairly Valued between 1.01 and -11.85, Overvalued between 1.01 and 7.44, and Strongly Overvalued above 7.44. The current Forward P/FCF of -2.62 falls within the Historic Trend Line -Fairly Valued range.

Cardiff Oncology Inc (CRDF) has a current Price-to-Book (P/B) ratio of 2.38. Compared to its 3-year average P/B ratio of 1.81 , the current P/B ratio is approximately 31.93% higher. Relative to its 5-year average P/B ratio of 2.50, the current P/B ratio is about -4.52% higher. Cardiff Oncology Inc (CRDF) has a Forward Free Cash Flow (FCF) yield of approximately -29.97%. Compared to its 3-year average FCF yield of -35.25%, the current FCF yield is approximately -14.97% lower. Relative to its 5-year average FCF yield of -26.48% , the current FCF yield is about 13.20% lower.

2.38

P/B

Median3y

1.81

Median5y

2.50

-29.97

FCF Yield

Median3y

-35.25

Median5y

-26.48

Competitors Valuation Multiple

The average P/S ratio for CRDF's competitors is 72.25, providing a benchmark for relative valuation. Cardiff Oncology Inc Corp (CRDF) exhibits a P/S ratio of 346.75, which is 379.91% above the industry average. Given its robust revenue growth of -25.77%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Lucid Diagnostics Inc

Anika Therapeutics Inc

Anteris Technologies Global Corp

Orchestra Biomed Holdings Inc

45.39

7.46%

147.30M

Performance Decomposition

Market capitalization of CRDF decreased by 21.35% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -7.23K to -11.52K.

The secondary factor is the Revenue Growth, contributed -25.77%to the performance.

Overall, the performance of CRDF in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-25.77%

163.00K → 121.00K

Revenue Growth

59.47%

-7.23K → -11.52K

Margin Expansion

-55.05%

-5.36 → -2.41

P/E Change

-21.35%